Control of <scp>NF</scp>‐<scp>kB</scp> activity in human melanoma by bromodomain and extra‐terminal protein inhibitor <scp>I</scp>‐<scp>BET</scp>151
Stuart Gallagher(Centenary Institute), Peter Hersey(The University of Sydney), Branka Mijatov(The University of Sydney), Jessamy Tiffen(The University of Sydney), Grant A. McArthur(The University of Melbourne), Peter J. Tummino(Intarcia Therapeutics (United States)), Carleen Cullinane(Peter MacCallum Cancer Centre), Dilini Gunatilake(The University of Sydney), Helen Rizos(Macquarie University), W. Freeman James(Melanoma Institute Australia), Gulietta M. Pupo(Westmead Hospital), Lei Jin(Air Force Medical University), Kavitha Gowrishankar(Westmead Institute)
Cited by 83
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k